Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 5/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12128199 | 0.87 | APP (0.35) | APPHTR6PTGDR2 | |
| SCHEMBL12128292 | 0.86 | APP (0.35) | APPHTR6PTGDR2 | |
| SCHEMBL12132048 | 0.86 | PTGDR2 (0.37) | PTGDR2 | |
| SCHEMBL12128227 | 0.85 | KEAP1 (0.36) | PTGDR2 | |
| SCHEMBL21088212 | 0.84 | HTR6 (0.34) | HTR6PTGDR2 | |
| SCHEMBL12127658 | 0.81 | HTR6 (0.41) | HTR6PTGDR2 | |
| SCHEMBL21089058 | 0.81 | PTGDR2 (0.38) | HTR6PTGDR2 | |
| SCHEMBL21088408 | 0.81 | PTGDR2 (0.34) | PTGDR2 | |
| SCHEMBL12128294 | 0.79 | PTGDR2 (0.32) | APPHTR6PTGDR2 | |
| SCHEMBL12127951 | 0.79 | GALR1 (0.39) | HTR6PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158242-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | AC IMMUNE SA (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20160158242-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | AC IMMUNE SA (CH) | 2016-06-09 | — | — | US | disclosed |
| US-9221812-B2 | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2015-12-29 | — | — | US | disclosed |
| US-9221812-B2 | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins | AC IMMUNE SA (CH) | 2015-12-29 | — | — | US | disclosed |
| US-20110280808-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | AC IMMUNE, S.A. (CH) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280808-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | APP, PSEN1, PSEN2 | APP 1/4885HTR6 2408/4885PTGDR2 1416/4885 |
| US-20160158242-A1 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins | APP, PSEN1, PSEN2 | APP 1/4885HTR6 2408/4885PTGDR2 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.